Griffin Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Griffin Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-8,228	Closed	-$444K	–	216
2024 Q2	$444K	Sell	8,228 -2,250	-21%	-$130K	0.05%	163
2024 Q1	$714K	Buy	10,478 +25	+0.2%	+$1.79K	0.09%	149
2023 Q4	$654K	Buy	10,453 +352	+3%	+$19.5K	0.08%	155
2023 Q3	$458K	Buy	10,101 +6,359	+170%	+$328K	0.07%	163
2023 Q2	$210K	Buy	+3,742	New	+$212K	0.03%	205
2021 Q4	–	Sell	-3,082	Closed	-$345K	–	237
2021 Q3	$345K	Sell	3,082 -2,244	-42%	-$282K	0.04%	194
2021 Q2	$862K	Buy	5,326 +3,550	+200%	+$432K	0.1%	150
2021 Q1	$216K	Buy	+1,776	New	+$268K	0.03%	226
2019 Q3	–	Sell	-1,360	Closed	-$64K	–	281
2019 Q2	$64K	Buy	+1,360	New	+$54.4K	0.01%	335

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Griffin Asset Management's CRSP Position: Q3 2024 in Review

Griffin Asset Management sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 8,228 shares — an estimated $444K sold.

Griffin Asset Management first reported a position in CRSP in Q2 2019 and held it in 9 quarters. The position peaked at $862K in Q2 2021. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

Griffin Asset Management reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
Griffin Asset Management sold 8,228 CRISPR Therapeutics shares in Q3 2024, an estimated $444K.
Griffin Asset Management first reported a position in CRISPR Therapeutics in Q2 2019 and held it in 9 quarters.
Griffin Asset Management's CRISPR Therapeutics position peaked at $862K in Q2 2021.
416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Griffin Asset Management's 13F filing for Q3 2024, filed 15 Oct 2024.